Is Charles River Laboratories International, Inc. (CRL) a Buy, Sell, or Hold?
NYSE : CRL
Charles River Laboratories International, Inc.
$224.35 USD
-$4.81 (-2.1%)
- Volume
- 571.48K
- Average Volume
- 877.78K
- Market Capitalization
- $10.81B
- P/E Ratio
- -59.83
- Dividend Yield
- 0.00%
- Price Target
- $220.00
- Year High
- $237.86
- Year Low
- $144.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.36
Company Overview
NYSE
Birgit Girshick
Medical - Diagnostics & Research
Healthcare
CRL
19700
US
USD
Liquidity Metrics
1.04
1.36
1.03
0.18
0.00
Sales & Valuation
$4.02B
2.68
3.73
27.62
7.99
Profitability
-$2.91
-$144.34M
-4.59%
-4.11%
-5.74%
-2.39%
P/E Metrics
-59.83
0.59
0.59
Analyst Price Target & Rating
$220.00
$260.00
$213.00
2/5
37 Analysts
1.98%
Poll Results
About Charles River Laboratories International, Inc. (NYSE:CRL) Stock
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It al ... so offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
2026-07-17 13:01:12
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
2026-07-14 13:10:32
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2026-07-13 09:00:00
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,
2026-07-13 08:00:00
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA.
Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able
2026-07-07 11:33:38
The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later to a new high for the year, implying optimism about the future path. Achieve is, in my view, a more derisked case now, thanks to successful financing, progress on shifting its supply chain, and new leadership. Despite the CRL, ACHV continues to advance. The denial was not drug-related, pointing towards a possible successful outcome in this story.
2026-07-03 12:25:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
LH or CRL: Which Is the Better Value Stock Right Now?
2026-07-01 12:40:29
Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
Is This the Right Time to Hold CRL Stock in Your Portfolio?
2026-07-01 10:30:52
Charles River Laboratories International, Inc. CRL is well-poised to grow in the coming quarters owing to the strength of its Research Models and Services (“RMS”) business and broader CRADL adoption. Strategic deals continue to broaden its capabilities while streamlining its portfolio.
Frequently Asked Questions
-
What is the current Charles River Laboratories International, Inc. (CRL) stock price?
-
Charles River Laboratories International, Inc.(NYSE:CRL) stock price is $224.35 in the last trading session. During the trading session, CRL stock reached the peak price of $237.86 while $144.26 was the lowest point it dropped to. The percentage change in CRL stock occurred in the recent session was --2.1% while the dollar amount for the price change in CRL stock was -$4.81.
-
CRL's industry and sector of operation?
-
The NYSE listed CRL is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of CRL?
-
Joseph W. LaPlume | Corporate Executive Vice President of Corporate Development & Strategy
Julie Frearson | Corporate Senior Vice President & Chief Scientific Officer
Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services
Michael Gunnar Knell | Corporate Senior Vice President & Chief Accounting Officer
Todd Spencer | Corporate Vice President of Investor Relations -
How many employees does CRL have?
-
Number of CRL employees currently stands at 19700. CRL operates from 251 Ballardvale Street, Wilmington, MA 01887, US.
-
Link for CRL official website?
-
Official Website of CRL is: https://www.criver.com
-
How do I contact CRL?
-
CRL could be contacted at phone #781 222 6000 and can also be accessed through its website. CRL operates from 251 Ballardvale Street, Wilmington, MA 01887, US.
-
How many shares of CRL are traded daily?
-
The average number of CRL shares traded daily for last 3 months was 877.78K.
-
What is the market cap of CRL currently?
-
The market value of CRL currently stands at $10.81B with its latest stock price at $224.35